TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32475902
Drug: Repaglinide-based combination
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide-based combination therapy with alogliptin
Study: 32475902
Drug: Miglitol-based combination
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol-based combination therapy with alogliptin
Study: 32475902
Drug: Miglitol monotherapy
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol monotherapy
Study: 32475902
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with alogliptin
Study: 33769243
Drug: ZnCl2 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnCl2 (1.5 µg/ml)
Study: 33769243
Drug: Na2SeO3 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na2SeO3 (5 µg/l)
Study: 33769243
Drug: ZnCl2 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnCl2 + Na2SeO3 (1.5 µg/ml + 5 µg/l)
Study: 35747142
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Engerix‐B, 20 μg/time) administered subcutaneously/intramuscularly at weeks 0, 4, and 24
Study: 35747142
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Engerix‐B)
Study: 35468736
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) program, 9 weeks
Study: 32533295
Drug: Internet-Delivered Parent-Child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-Delivered Parent-Child Interaction Therapy (iPCIT)
Study: 32533295
Drug: Standard, clinic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard, clinic-based Parent-Child Interaction Therapy (PCIT)
Study: 36274681
Drug: Enamel matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel matrix derivative administration
Study: 34959861
Drug: Combination (BOTH)
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (BOTH)
Study: 35732969
Drug: Juvenile Drug
Normalized name: CUNNINGHAM CLAMP,JUVENILE,BARD #004052
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juvenile Drug Treatment Courts (JDTC)
Study: 35164524
Drug: Lithium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium plus antipsychotics (Li+AP) (N = 50, primarily quetiapine and aripiprazole)
Study: 35164524
Drug: Lithium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium plus anticonvulsants (Li+AC) (N = 107, primarily lamotrigine and valproate)
Study: 35164524
Drug: Lithium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium plus antipsychotics and anticonvulsants (Li+AP+AC) (N = 73)
Study: 35164524
Drug: Lithium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium plus antipsychotics (Li+AP)
Study: 32044039
Drug: Motor Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor Learning (ML) Group
Study: 35383052
Drug: HIV/TB syndemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV/TB syndemic impact on attitudes towards TB treatment
Study: 32290852
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day synbiotic (Familact) for 12 weeks
Study: 35422467
Drug: Lamotrigine (pre-treatment)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (pre-treatment)
Study: 32555927
Drug: Levosimendan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (12 µg/kg bolus)
Study: 34965784
Drug: Resourcefulness intervention
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resourcefulness intervention (teaching on social and personal resourcefulness skills, access to intervention video, skill application video-vignettes, four weeks of skills reinforcement using daily logs, four weekly phone contacts, booster sessions at two- and four-month postenrollment)
Study: 33734306
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (2 mg) quarterly for 24 months
Study: 33734306
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection quarterly for 24 months
Study: 32501541
Drug: IM doravirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM doravirine 200 mg (Treatment A: 1×1 mL, 20% suspension)
Study: 32501541
Drug: IM doravirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM doravirine 300 mg (Treatment B: 1×0.66 mL, 30% suspension)
Study: 32501541
Drug: IM doravirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM doravirine 200 mg (Treatment C: 2×0.5 mL, 20% suspension)
Study: 32501541
Drug: Oral doravirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doravirine
Study: 35627562
Drug: Marine therapy
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine therapy group (MTG)
Study: 616759071
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta‐TCP and rhGDF‐5 (400 mug)
Study: 616759071
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta‐TCP and rhGDF‐5 (800 mug)
Study: 35660485
Drug: Algorithm-based FiO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-based FiO2 titration with electronic medical record-based automated alerts
Study: 35660485
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice FiO2 titration
Study: 33388697
Drug: Routine speech
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine speech therapy (Control)
Study: 33507315
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided quadratus lumborum block (QLB) using 0.5 mL/kg body weight 0.25% bupivacaine preoperatively
Study: 32506135
Drug: Potassium supplementation
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplementation (3 g/d)
Study: 32506135
Drug: Sodium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium supplementation (3 g/d)
Study: 32053816
Drug: Contrast-enhanced ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound (CEUS) performed 48 hours after treatment
Study: 32053816
Drug: CEUS responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CEUS responders (48 h after treatment)
Study: 35896969
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron therapy and exercise training
Study: 34275501
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral vitamin D3 drops (3‐12 months: 2000 IU; >12 months‐5y: 4000 IU; n=33) for 12 weeks
Study: 34275501
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral depot dose of vitamin D3 granules (3‐12 months: 60,000 IU; >12 months‐5y: 150,000 IU; n=33) for 12 weeks
Study: 35007624
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg subcutaneous every 4 weeks
Study: 32460885
Drug: NHS Speech
Normalized name: (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHS Speech and Language Therapy (SLT)
Study: 32460885
Drug: Lee Silverman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lee Silverman Voice Treatment (LSVT LOUD®)
Study: 34846593
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (E) - chest drain removal at 5 ml/kg daily output
Study: 34846593
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) - chest drain removal at less than 250 ml/day
Study: 33225492
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment (all groups)
Study: 33271536
Drug: Active learning
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active learning program (90-min sessions weekly for 24 weeks)
Study: 35045362
Drug: V591 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: V591 (low dose, 1 × 10^5 TCID50)
Study: 35045362
Drug: V591 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: V591 (high dose, 1 × 10^6 TCID50)
Study: 35045362
Drug: V591 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: V591 (two injections)
Study: 35045362
Drug: V591 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: V591 (low dose, two injections)
Study: 35045362
Drug: V591 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: V591 (high dose, two injections)
Study: 36420365
Drug: Functional and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional and Kinetic Treatment with Rehabilitation (FAKTR) combined with cryotherapy
Study: 32247315
Drug: Control (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normal saline lubrication without BH spray)
Study: 33107977
Drug: Tissue level
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue level implants with a partially smooth collar in thin phenotype group (n=13)
Study: 33107977
Drug: Tissue level
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue level implants with a partially smooth collar in thick phenotype group (n=13)
Study: 36195338
Drug: LYS006 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYS006 5 mg once daily
Study: 36195338
Drug: LYS006 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYS006 15 mg once daily
Study: 36195338
Drug: LYS006 20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYS006 20-80 mg twice a day
Study: 36195338
Drug: LYS006 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYS006 (various doses)
Study: 35317736
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (Observation of naturalistic scenes + Virtual Reality) (CO + VR)
Study: 32054536
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin (35 mg/kg) alongside standard TB treatment
Study: 32054536
Drug: Standard-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose rifampicin alongside standard TB treatment
Study: 34105866
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 300 mg capsule twice daily for 3 months
Study: 33185376
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.5% bupivacaine at 23°C
Study: 33185376
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.5% bupivacaine warmed to 37°C
Study: 35803088
Drug: 600mg lavender
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg lavender flowers capsules, taken three times daily for 60 days
Study: 35803088
Drug: 600mg cornstarch
Normalized name: cornstarch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg cornstarch capsules, taken three times daily for 60 days
Study: 32773737
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (GA) and postoperative intravenous analgesia (Group A)
Study: 32773737
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (GA) combined with thoracic epidural anesthesia (TEA) and postoperative intravenous analgesia (Group C)
Study: 34128083
Drug: Rivaroxaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (2.5 mg bid)
Study: 36368677
Drug: Isomyosamine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomyosamine 150 mg, 300 mg, 450 mg (single daily doses for 3 days)
Study: 36368677
Drug: Isomyosamine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomyosamine 600 mg (multiple daily doses for 6 days)
Study: 36368677
Drug: Isomyosamine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomyosamine (various doses)
Study: 36368677
Drug: Isomyosamine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomyosamine 300 mg to 600 mg (single dose)
Study: 36368677
Drug: Isomyosamine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomyosamine 600 mg (once daily for 5 days)
Study: 36368677
Drug: Isomyosamine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomyosamine (all doses)
Study: 33491389
Drug: PerioTabs (NitrAdine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: PerioTabs (NitrAdine-based gingiva brushing solution) for 10 days
Study: 35684144
Drug: HMB-enriched oral
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-enriched oral nutritional supplement (1.5 g of calcium HMB per bottle, twice a day for 12 weeks)
Study: 35684144
Drug: HMB-free oral
Normalized name: Phillips' Cramp-free Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-free oral nutritional supplement (similar composition devoid of HMB, twice a day for 12 weeks)
Study: 35076302
Drug: Pavlik harness
Normalized name: HARNESS,PROREN UNDERGARMENT 2XL/3XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pavlik harness treatment
Study: 32558199
Drug: Belatacept maintenance
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belatacept maintenance therapy
Study: 32558199
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with rabbit antithymocyte globulin (rATG) induction, rapid steroid taper, and maintenance mycophenolate and tacrolimus
Study: 32891161
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of temporary suspension in clinical trials
Study: 35101098
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of rocuronium bromide for 48 hours
Study: 35343933
Drug: Subparaneural upper
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subparaneural upper trunk block (5 mL of 0.5% ropivacaine)
Study: 35343933
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block (15 mL of 0.5% ropivacaine)
Study: 32702309
Drug: Pazopanib (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (350 mg/m2 once daily for patients <18 years; 600 mg once daily for patients ≥18 years)
Study: 33335310
Drug: JNJ-42165279 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42165279 (100 mg)
Study: 32867830
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software, a prediction software based on proteomic biomarkers.
Study: 32867830
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of biotherapy based on current practice, without the SinnoTest® software (any biotherapy).
Study: 33543797
Drug: Energy-dense formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-dense formula (100 mL, 2 kcal/mL)
Study: 33543797
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula (200 mL, 1 kcal/mL)
Study: 32506227
Drug: FTL-assisted delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTL-assisted delivery of topical tranexamic acid (TXA)
Study: 35940932
Drug: Iodophor solution
Normalized name: iodophors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodophor solution
Study: 34766389
Drug: M. officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. officinalis capsules (400 mg/d; n = 23)
Study: 35041636
Drug: Hydrocodone/acetaminophen 5/325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen 5/325 mg
Study: 35041636
Drug: Ibuprofen/acetaminophen 600/325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/acetaminophen 600/325 mg
Study: 33197662
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil applied three times a day for five days after chemotherapy in addition to routine antiemetic treatment.
Study: 33197662
Drug: Routine antiemetic
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine antiemetic treatment only (Control group).
Study: 35870902
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide combined with intravenous hydrocortisone hemisuccinate (n = 23)
Study: 35870902
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline combined with intravenous hydrocortisone hemisuccinate (n = 27)
Study: 34498068
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g IV acetaminophen every six hours for 48 hours postoperatively
Study: 35818157
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy for pollen; 3 years of treatment.
Study: 35818157
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy for grass pollen, house-dust mite, or Japanese cedar; duration not specified.
Study: 35818157
Drug: Both sublingual
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sublingual and subcutaneous grass pollen immunotherapies; 2 years of treatment.
Study: 36364765
Drug: Drinking speed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking speed of 20 mL/5 min
Study: 36364765
Drug: Drinking speed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking speed of 40 mL/5 min
Study: 36364765
Drug: Drinking speed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking speed of 80 mL/5 min
Study: 34428832
Drug: Vancomycin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (7 days of oral intake)
Study: 32565594
Drug: Vilazodone 20
Normalized name: vilazodone 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone 20 mg daily
Study: 32565594
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg daily
Study: 33560411
Drug: i.v. ghrelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ghrelin administration
Study: 33704530
Drug: standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard induction chemotherapy
Study: 33039693
Drug: Semaglutide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide (0.1 mg, 0.2 mg, 0.4 mg)
Study: 34363051
Drug: Home-based transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based transcutaneous electrical acupoint stimulation (TEAS) for 12 weeks, 4 weekly sessions
Study: 34363051
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (continuation of antihypertensive drugs and lifestyle education)
Study: 32639394
Drug: Ketotifen fumarate
Normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen fumarate (KF) 5 mg orally twice daily for 6 weeks
Study: 32639394
Drug: Lactose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose placebo (PL) orally twice daily for 6 weeks
Study: 33653754
Drug: Vibration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration therapy coupled with protocolised mobilisation
Study: 32024955
Drug: Osmotically controlled
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotically controlled Eperisone 150 mg tablets
Study: 32024955
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release Eperisone tablets (reference formulation)
Study: 34691212
Drug: DHEA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (25 mg orally 3 times a day for 90 days)
Study: 32599738
Drug: Cereal A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal A (0% whole grain flour, high sugar content, 24 g/100 g)
Study: 32599738
Drug: Cereal B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal B (50% whole grain flour, medium sugar content, 12 g/100 g)
Study: 32777383
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin treatment for 24 weeks
Study: 35981270
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (modified folinic acid-fluorouracil-oxaliplatin 6 or capecitabine-oxaliplatin) for 3 months followed by transanal excision surgery (TES)
Study: 35981270
Drug: Transanal excision
Normalized name: pNF1-Blast Excised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transanal excision surgery (TES) after chemotherapy
Study: 35981270
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life and rectal function scores
Study: 32187464
Drug: Lopinavir-ritonavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care
Study: 35465733
Drug: trastuzumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab + chemotherapy (eribuline, capecitabine or vinorelbine)
Study: 34582451
Drug: Ready-to-use supplementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use supplementary food (RUSF) plus anti-infective therapies (azithromycin, more frequent IPTp, testing/treatment for vaginal dysbiosis)
Study: 34582451
Drug: Ready-to-use supplementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use supplementary food (RUSF) plus anti-infective therapies